Jan. 14, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with ...

Kymera Therapeutics, Inc. KYMR shares rallied 7.8% in the last trading session to close at $40.12. This move can be attributable to notable volume with a higher number of shares being traded than ...

Kymera Therapeutics, Inc. announced its participation in two upcoming investor events: the Guggenheim SMID Cap Biotechnology Conference on February 6 and the Oppenheimer 35th Annual Healthcare ...

Begin your TipRanks Premium journey today. Kymera Therapeutics (KYMR) Company Description: Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating ...

US biotech Kymera Therapeutics has begun a strategic collaboration with Sanofi to develop and market several drugs tackling immune-inflammatory disease, which could be worth up to $2 billion. The ...

Kymera Therapeutics announced its clinical development plans for 2025, focusing on its oral degrader programs targeting immunological diseases. The company is currently conducting a Phase 1 trial ...

KBC Group NV boosted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 53.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,151 shares of the company’s ...

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader ...

Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases ...